Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease
Mitral Valve Repair Using Flexible Bands Versus Complete Rings in Patients With Degenerative Mitral Valve Disease: a Prospective, Randomized Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- severe primary mitral regurgitation due to degenerative mitral valve disease
Exclusion Criteria:
- previous open cardiac surgery,
- indication for concomitant aortic valve replacement,
- left ventricle impairment (ejection fraction < 40%).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Flexible band
Mitral valve repair with flexible posterior annuloplasty band
|
Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
|
|
Active Comparator: Complete ring
Mitral valve repair with complete rigid ring
|
Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Freedom from significant mitral regurgitation
Time Frame: 12 months
|
Significant mitral regurgitation is defined as moderate and severe mitral regurgitation.
The severity of MR was evaluated and defined in accordance with the European Association of Echocardiography recommendations for the assessment of valvular regurgitation
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Survival
Time Frame: 12 months, 24 months
|
Continued existence at follow up
|
12 months, 24 months
|
|
Freedom from reoperations
Time Frame: 12 months, 24 months
|
Freedom from redo mitral valve surgery during follow up
|
12 months, 24 months
|
|
Freedom from severe MR recurrence
Time Frame: 12 months
|
The severity of MR was evaluated and defined in accordance with the European Association of Echocardiography recommendations for the assessment of valvular regurgitation
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 25041214
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitral Regurgitation
-
NCT00800046CompletedMitral Regurgitation | Mitral Valve Regurgitation | Functional Mitral Regurgitation
-
NCT04350372CompletedFunctional Mitral Regurgitation | Degenerrative Mitral Regurgitation
-
NCT05865938CompletedMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve Regurgitation
-
NCT06814210Not yet recruitingMitral Regurgitation | Functional Mitral Regurgitation | Degenerative Mitral Valve Regurgitation
-
NCT07227675CompletedMitral Regurgitation | Mitral Valve Regurgitation
-
NCT04396379Not yet recruitingIschemic Mitral Regurgitation | Functional Mitral Regurgitation
-
NCT02520310CompletedMitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With Insufficiency
-
NCT06876883RecruitingMitral Insufficiency | Mitral Regurgitation (MR)
-
NCT02592889UnknownMITRAL REGURGITATION
-
NCT03706833Active, not recruitingMitral Regurgitation | Mitral Insufficiency | Functional Mitral Regurgitation | Degenerative Mitral Valve Disease
Clinical Trials on Mitral valve repair
-
NCT07284212CompletedPediatric Cardiac Surgery | Mitral Regurgitation (MR)
-
NCT05714228CompletedMitral Valve Regurgitation
-
NCT05839782CompletedDegenerative Mitral Valve Disease
-
NCT01156441WithdrawnMyocardial Infarction | Mitral Regurgitation
-
NCT03567668UnknownPulmonary Arterial Hypertension | Mitral Insufficiency
-
NCT04954404Recruiting
-
NCT00807040CompletedCoronary Artery Disease | Mitral Valve Insufficiency
-
NCT02054221CompletedHypertrophic Obstructive Cardiomyopathy
-
NCT04780607RecruitingOutcomes of Mitral Valve Surgery in Patients Affected by Rheumatic Heart Disease